Formycon acquires biosimilar assets from ATHOS KG in strategic partnership

Formycon AG and ATHOS KG have agreed to merge biosimilar development activities. Formycon will acquire 100% of rights in FYB202, the 50% stake in FYB201, and Bioeq GmbH for a cumulative consideration of approximately EUR 650 million. ATHOS will become the largest shareholder with about 26.6% of Formycon.

“Formycon and ATHOS KG have agreed to merge their development activities in the area of biosimilars through a long-term strategic partnership.”formycon.com

• 1 source
• formycon.comFormycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership - Formycon AGMar 29, 2022

Summarized from public sources; check the original articles before acting on it.